Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $135.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price lifted by Guggenheim from $125.00 to $135.00 in a research note published on Tuesday morning, MarketBeat reports. Guggenheim currently has a buy rating on the stock.

Several other equities analysts have also commented on KYMR. Canaccord Genuity Group upped their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. B. Riley Financial boosted their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, June 29th. BTIG Research restated a “buy” rating and set a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Finally, Morgan Stanley restated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.48.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $107.01 on Tuesday. The firm’s 50-day moving average is $98.43 and its two-hundred day moving average is $87.56. Kymera Therapeutics has a 12 month low of $36.65 and a 12 month high of $130.05. The stock has a market capitalization of $8.80 billion, a P/E ratio of -29.97 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) earnings per share. As a group, analysts anticipate that Kymera Therapeutics will post -3.28 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the sale, the director directly owned 472,267 shares of the company’s stock, valued at $52,086,327.43. This represents a 49.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 3,607,813 shares of company stock worth $387,818,004. 15.98% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the period. Smartleaf Asset Management LLC increased its holdings in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC raised its position in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics in the 4th quarter valued at about $63,000. Finally, Osaic Holdings Inc. raised its position in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.